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ABSTRACT
Introduction: To assess the efficacy and safety
of vildagliptin as add-on therapy in Japanese
patients with type 2 diabetes mellitus (T2DM),
inadequately controlled on stable long-acting,
intermediate-acting, or pre-mixed insulin, with
or without concomitant metformin.
Methods: In this 12-week placebo-controlled
study, patients were randomized to receive
either vildagliptin 50 mg twice daily (bid) or
placebo treatment in a 1:1 ratio. The primary
endpoint was change in glycated hemoglobin A1c
(HbA1c) from baseline to 12-week endpoint.
Secondary endpoints included proportion of
patients achieving pre-defined HbA1c targets of
B6.5%,\7.0%, and HbA1c\7.0% in patients with
baseline HbA1c B8.0% and change in fasting
plasma glucose (FPG) after 12 weeks of treatment.
Regular monitoring was performed to record any
treatment-emergent adverse events (AEs) and
serious adverse events or hypoglycemic episodes.
Results: Of the 156 patients randomized,
96.8% completed the study (vildagliptin,
n = 76; placebo, n = 75). Patient demographics
and clinical characteristics were comparable
between the groups at baseline. Addition of
vildagliptin resulted in statistically significant
reductions in HbA1c after 12 weeks
(-1.01 ± 0.06%), with a between-treatment
difference of -0.91 ± 0.09% (p\0.001). FPG
levels reduced from baseline to 12 weeks in the
vildagliptin group (-1.2 ± 0.2 mmol/L), with a
between-treatment difference of
-1.2 ± 0.3 mmol/L which was significant
(p\0.001). The proportion of patients
achieving HbA1c targets was higher with
vildagliptin treatment for all pre-defined
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responder rate categories. The overall incidence
of AEs was comparable between groups
(vildagliptin, 46.2% vs. placebo, 43.6%). The
overall incidence of hypoglycemic events was
low and all events were self-treatable without
using drug therapy. No severe hypoglycemic
events were reported.
Conclusion: Treatment with vildagliptin 50 mg
bid as add-on to insulin with or without
metformin resulted in statistically significant
reductions in HbA1c in Japanese patients with
T2DM. Overall, vildagliptin was well tolerated
with a safety profile similar to that of placebo in
this patient population.
ClinicalTrials.gov Identifier, NCT02002221
Funding: Novartis Pharma K.K
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INTRODUCTION
The increasing prevalence of type 2 diabetes
mellitus (T2DM) poses a major health crisis
globally. According to International Diabetes
Federation estimates, 382 million people were
affected with T2DM in 2013. This number is
projected to increase up to 600 million by 2035,
with Asia alone accounting for 60% of this
population [1].
In Japan, approximately 7 million people
aged 20–79 years are affected with T2DM and
the prevalence is dramatically increasing due to
lifestyle changes, genetic predisposition, and
the aging population [2, 3]. Mortality related to
diabetes was 44% in patients aged\60 years in
Japan, China, and other parts of the Western
Pacific region [1]. The high prevalence of T2DM
is associated with significant economic
encumbrance, accounting for up to 6% of the
total healthcare budget [3].
Due to the progressive nature of T2DM,
treatment intensification with oral
antidiabetes drugs (OADs) is often required.
However, despite the availability of several
OADs and advancements in T2DM
management, achieving glycated hemoglobin
A1c (HbA1c) goal of\7% is still a challenge in
most Asian countries including Japan [4].
Impaired insulin secretion and insulin
resistance are two major pathophysiological
features where insulin secretory response is
severely impaired in T2DM patients, especially
among Japanese population [5].
In Japan, insulin is now being used more
frequently, with *30% of patients receiving
either a monotherapy or in combination with
other OADs [6, 7]. Although pre-mixed insulin
lowers fasting plasma glucose (FPG) and
post-prandial glucose levels to some extent, it
eventually fails to demonstrate adequate
control over glycemic excursions [7]. Fear of
increased risk of hypoglycemia and weight gain
associated with insulin often results in delay in
treatment initiation and intensification [8, 9].
In addition, patients undergoing insulin
treatment gradually develop a syndrome called
Impaired Awareness of Hypoglycemia (IAH), in
which the ability to identify the onset of
hypoglycemia becomes progressively impaired
and thus the complications associated with
hypoglycemia increase [10, 11].
Hence, there is a need for OADs as an add-on
to insulin that can improve glycemic control
without increasing the risk of hypoglycemia
and weight gain. Dipeptidyl peptidase-4 (DPP-4)
inhibitors such as vildagliptin are being
increasingly used for the treatment of diabetes
in Japanese patients [12]. Further, concomitant
use of insulin and a DPP-4 inhibitor has recently
been included in the treatment algorithm [6].
The efficacy and tolerability of vildagliptin in
combination with insulin, with or without
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metformin, has been demonstrated in
randomized clinical trials in global populations
including Asians [13–15]. However, there is still a
dearth of data on the efficacy and safety of
vildagliptin as an add-on therapy to insulin in
Japanese patients with T2DM.
This 12-week, randomized, placebo-controlled
study aimed to assess the efficacy and safety of
vildagliptin 50 mg twice daily (bid) add-on
therapy in Japanese patients with T2DM,
inadequately controlled on insulin, with or
without concomitant metformin treatment.
METHODS
Study Design and Patient Population
This was a 12-week, randomized, double-blind,
placebo-controlled study conducted in Japan.
Patients were treated with stable once daily (qd)
or bid injectable doses (B1 unit/kg/day) of
long-acting, intermediate-acting, or pre-mixed
insulin, with or without metformin, for at least
12 weeks prior to screening. Patient visits were
scheduled at week -2 (visit 1), week 0,
(baseline), and at weeks 4, 8, and 12 (visits 2,
3, and 4, respectively; Fig. 1).
Following a 2-week screening period, men
and women, aged between 20 and 75 years,
with baseline HbA1c 7–10%, body mass index
(BMI) 20–35 kg/m2, fasting C-peptide C0.6 ng/
mL (C0.20 nmol/L), and inadequately
controlled on insulin with or without
metformin, were randomized. Patients with a
history of type 1 diabetes, FPG levels
C15.0 mmol/L, acute metabolic complications
such as ketoacidosis or lactic acidosis, critical
liver conditions such as cirrhosis or hepatitis,
impaired renal function, congestive heart
failure (New York Heart Association Class III or
IV), myocardial infarction, stroke or ischemic
attacks in past 6 months were excluded from
the study. Patients who received rapid- or
short-acting insulin except in pre-mixed
formulations with either intermediate- or
long-acting insulin, or even those on insulin
doses taken more frequently than bid, or a total
insulin dose exceeding 1 unit/kg/day for the
past 12 weeks were also excluded. The dose of
insulin was to be maintained within 10%
variation from baseline throughout the study
unless dose adjustments were required for safety
reasons. Patients were stratified based on the use
of metformin and type of insulin.
Efficacy and Safety Assessments
The primary endpoint was the change in HbA1c
from baseline to 12 weeks. Secondary efficacy
endpoints included responder rates based on
Fig. 1 Study design. *Patients continued on a stable dose of
long-acting or intermediate-acting or pre-mixed insulin, and
metformin if applicable, throughout the study. BL€
Baseline, the ﬁrst day of blinded study medication. **Each
patient was instructed to visit the study site within
13 weeks from baseline. bid twice daily
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the proportion of patients achieving the
pre-defined glycemic targets of HbA1c B6.5%,
\7.0%, and HbA1c \7.0% in patients with
baseline HbA1c B8.0%, HbA1c reduction from
baseline to endpoint of C1% and C0.5%, and
change in FPG from baseline to study endpoint.
Subgroup analysis based on concomitant use of
metformin and insulin types were also
performed. Safety assessments included vital
signs, body weight, standard hematology,
urinalysis and biochemistry test results, as well
as recording and regular monitoring of
treatment-emergent adverse events (AEs) and
serious adverse events (SAEs). Patients were
educated on hypoglycemic symptoms in the
beginning of the screening period where
general reviews on possible triggers and
identification of symptoms were shared. At
baseline visit, patients were provided with a
personal calibrated home glucose monitor and
were asked to record the hypoglycemic events
in a glycemia study diary. Hypoglycemia was
defined as symptoms suggestive of
hypoglycemia that was further confirmed by a
self-monitored blood glucose measurement of
\3.1 mmol/L. The event was considered grade 1
if the patient was able to initiate self-treatment,
and grade 2 (severe hypoglycemia) if the patient
required assistance of another person or
hospitalization. All laboratory assessments
were performed at a central facility (LSI
Medience Corporation, Tokyo, Japan).
Statistical Analysis
Assuming a withdrawal rate of 5%, a sample size
of 152 patients with T2DM treated with insulin
were randomized to provide 90% power to
detect a clinically significant difference of
0.6% in HbA1c change from baseline between
vildagliptin and placebo at a one-sided
significance level of 2.5%. nQuery Advisor 7.0
(Statistical Solutions Ltd., Cork, Ireland) was
applied for the calculation of sample size based
on primary variables of change from baseline in
HbA1c at the week-12 endpoint.
Efficacy analyses were performed on the full
analysis set (FAS) population, comprising all
randomized patients who received at least one
dose of study medication and had one
post-randomization efficacy measurement. An
analysis of covariance (ANCOVA) model, with
treatment, type of insulin (long- or
intermediate-acting vs. pre-mixed), and use of
metformin as classification variables and
baseline HbA1c as a covariate, was used to
compare the treatment effect in HbA1c
reduction after 12 weeks. Changes in FPG
levels from baseline to week 12 were also
analyzed using ANCOVA model. The least
square mean change and difference from
baseline for each treatment group, and the
associated one-sided 95% confidence interval
(CI) and p value for each difference was
obtained from the primary analysis model.
The percentage of patients who met each of
the pre-defined responder criteria was
computed and compared using a Chi-Squared
test in the FAS. For subgroup analysis, summary
of absolute values and changes in HbA1c from
baseline to study endpoint were presented on
the last observation carried forward-based data
for the FAS. Safety analyses were performed on
the safety set which included all the patients
who received at least one dose of the study drug
and were summarized descriptively. All the data
analysis for this study was performed using
SAS statistical software (version 9.3, SAS
Institute Inc., Cary, NC, USA).
Ethics and Good Clinical Practice
The study protocol was reviewed and approved
by the Independent Ethics Committee/
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Institutional Review Board at each participating
center. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national),
the Declaration of Helsinki of 1964, as revised in
2013 and Good Clinical Practice guidelines.
Written informed consent was obtained from
all patients prior to inclusion in the study. The
study is registered with ClinicalTrials.gov,
identifier: NCT02002221.
RESULTS
Patient Disposition and Baseline
Characteristics
A total of 275 patients were screened based on
inclusion/exclusion criteria.
Unacceptable laboratory values accounted for
68.9% (n = 119) of screening failures. Out of
156 patients randomized, 96.8% (vildagliptin,
n = 76 and placebo, n = 75) completed the
study (Fig. 2). The most common reason
behind discontinuation was AEs: 2.6% in the
vildagliptin and 1.3% in the placebo group.
Demographics and baseline characteristics of
the patients are presented in Table 1. Both
treatment groups were well balanced for
baseline characteristics. Men predominated
over women (71.2% vs. 28.8%, respectively).
The overall mean age ± SD was 59.3 ± 9.3 years,
mean BMI was 25.7 ± 3.3 kg/m2, mean baseline
HbA1c was 8.1 ± 0.8%, and mean FPG was
8.9 ± 2.6 mmol/L. The mean duration of
T2DM was *13 years. More patients were on
intermediate-acting insulin (n = 91) compared
to pre-mixed insulin (n = 65). The mean daily
doses of insulin and metformin were
0.3 ± 0.18 unit/kg/day, and 1047.8 mg/day,
respectively.
Efficacy
The mean change in HbA1c over 12 weeks of
treatment is represented in Fig. 3a. Vildagliptin
demonstrated consistent reductions in mean
HbA1c compared to placebo throughout the
study. The adjusted mean change in HbA1c
from baseline to study endpoint was
-1.01 ± 0.06 and -0.11 ± 0.06% in the
vildagliptin and placebo groups, respectively,
with a between-treatment difference of
-0.91 ± 0.09% (p\0.001) (Fig. 3b). The
proportion of patients achieving target HbA1c
\7% were distinctly higher in the vildagliptin
group compared to placebo for all pre-defined
responder categories (Table 2). Half the patients
(38 out of 76) in the vildagliptin group achieved
HbA1c target\7%, compared with 3.9% in the
placebo group. In all the subgroups by
concomitant metformin use or insulin type,
vildagliptin resulted in higher HbA1c
reductions than placebo (Table 3). Reductions
in FPG were also consistent throughout the
study (Fig. 4a). The adjusted mean change in
FPG from baseline to endpoint was -1.2 ± 0.2
vs. -0.02 ± 0.2 mmol/L in the vildagliptin and
placebo groups, respectively, with a between-
treatment difference of -1.2 ± 0.3 mmol/L
(p\0.001; Fig. 4b).
Safety
Vildagliptin 50 mg bid added to long-acting,
intermediate-acting or pre-mixed insulin, with
or without metformin was generally safe and
well tolerated. The overall incidence of AEs was
similar and comparable between the
vildagliptin (46.2%) and placebo (43.6%)
groups (Table 4). The most frequent AEs were
of the primary system organ class, ‘‘infections
and infestations’’ with a slightly lower incidence
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in the vildagliptin group compared with
placebo group (15.4% vs. 19.2%, respectively).
The incidence of AEs was higher in the
vildagliptin group for metabolism and
nutrition disorders (6.4% vs. 1.3%) compared
with placebo. The overall incidence of AEs
suspected to be drug related was higher with
vildagliptin (23.1%) compared with placebo
(12.8%), and this difference was mainly due to
events of hunger and hyperhidrosis. No deaths
were reported during the study. The incidence
of SAEs was infrequent in either of the
treatment groups (2.6% in vildagliptin vs.
1.3% in placebo). Body weight remained
almost unaltered throughout the study in the
vildagliptin group (1.09 kg). The proportion of
patients experiencing hypoglycemic events was
higher in the vildagliptin group (6.4%, 5
patients) than placebo (1.3%, 1 patient). Nine
hypoglycemic events were reported in the
vildagliptin group as opposed to 1 event in the
placebo group (Table 5). Of the 9 events, 3 were
triggered by strenuous exercise, 3 events by
missed/delayed meals, and the remaining 3
events had no precipitating events specified.
However, there was no severe hypoglycemia or
any event reported, leading to study drug
discontinuation. The overall incidence of
hypoglycemic events was low and all




parallel-group study is the first report to
demonstrate the efficacy and safety of
vildagliptin 50 mg bid as add-on therapy in
Fig. 2 Patient disposition
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Japanese patients inadequately controlled on
insulin, with or without concomitant
metformin. In this study, vildagliptin
treatment was well tolerated with a safety
profile similar to placebo group and the results
were consistent with earlier studies [13–15].
Vildagliptin 50 mg bid treatment
demonstrated a clinically and statistically
Table 1 Patient demographics and baseline characteristics (randomized set)
Parameters Vildagliptin





Age (years) 58.5 ± 9.6 60.1 ± 9.1 59.3 ± 9.3
C65 years, n (%) 27 (34.6) 28 (35.9) 55 (35.3)
Men, n (%) 55 (70.5) 56 (71.8) 111 (71.2)
Body weight (kg) 68.9 ± 11.6 70.4 ± 12.3 69.7 ± 11.9
BMI (kg/m2) 25.3 ± 3.4 26.0 ± 3.1 25.7 ± 3.3
HbA1c (%) 8.1 ± 0.8 8.1 ± 0.9 8.1 ± 0.8
FPG (mmol/L) 9.0 ± 3.0 8.7 ± 2.0 8.9 ± 2.6
C8.9 mmol/L, n (%) 32 (41.0) 32 (41.0) 64 (41.0)
Duration of T2DM (years) 12.8 ± 9.0 12.9 ± 8.1 12.9 ± 8.6
eGFR (MDRD), mL/min/1.73 m2, n (%)
Normal,[80 65 (83.3) 59 (75.6) 124 (79.5)
Mild, C50 to B80 12 (15.4) 18 (23.1) 30 (19.2)
Moderate, C30 to\50 1 (1.3) 1 (1.3) 2 (1.3)
Background therapy
Insulin dose (unit/kg/day) 0.3 ± 0.17 0.3 ± 0.20 0.3 ± 0.18
Insulin with concomitant metformin, n (%) 34 (43.6) 34 (43.6) 68 (43.6)
Long- or Intermediate-acting, n (%) 21 (26.9) 20 (25.6) 41 (26.3)
Pre-mixed, n (%) 13 (16.7) 14 (17.9) 27 (17.3)
Insulin without concomitant metformin, n (%) 44 (56.4) 44 (56.4) 88 (56.4)
Long- or Intermediate-acting, n (%) 25 (32.1) 25 (32.1) 50 (32.1)
Pre-mixed, n (%) 19 (24.4) 19 (24.4) 38 (24.4)
Metformin (n) 34 34 68
Metformin total daily dose (mg/day) 1022.1 ± 497.6 1073.5 ± 446.1 1047.8 ± 469.7
B750 mg, n (%) 17 (21.8) 11 (14.1) 28 (17.9)
[750 mg, n (%) 17 (21.8) 23 (29.5) 40 (25.6)
Data are expressed as mean ± SD, unless speciﬁed otherwise
bid twice daily, BMI body mass index, eGFR estimated glomerular ﬁltration rate, FPG fasting plasma glucose, HbA1c
glycated hemoglobin, MDRD modiﬁcation of diet in renal disease, SD standard deviation, T2DM type 2 diabetes mellitus
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significant (p\0.001) reduction in HbA1c, with
a between-treatment difference of -0.91% after
12 weeks. Vildagliptin-mediated change in
HbA1c was similar in patient subgroups
treated with or without concomitant
metformin. The efficacy results from this study
are consistent with findings from previous trials
conducted in Caucasian and Asian populations
[13–15]. Vildagliptin treatment also resulted in
significant reductions in FPG levels when
compared with placebo, with a
between-treatment difference of -1.2 mmol/L
(p\0.001) which is comparable with previous
findings from a 24-week clinical trial (a
reduction of -0.8 mmol/L in mean FPG from a
baseline of 9.3 mmol/L) [13]. Within subgroups
based on insulin type as well as metformin use,
vildagliptin demonstrated significantly marked
reductions in HbA1c from baseline to endpoint,
compared with placebo.
Similar and consistent differences in HbA1c
values were observed in all responder rate
categories. Half the patients in vildagliptin
group achieved an HbA1c target \7%.
Differences between treatment with
vildagliptin and placebo were statistically
significant for all responder rate categories.
Vildagliptin was well tolerated with overall
incidence rate of AEs similar to that of placebo
(46.2%, vildagliptin vs. 43.6%, placebo). The
incidence of hyperhidrosis, hunger, tremor, and
hypoglycemia was more common in the
vildagliptin group than in the placebo group.
The percentage of patients discontinued due to
AEs was low and comparable between treatment
groups. There were no patients with
treatment-emergent hepatic enzyme elevation
or deaths reported in the study. The overall
incidence of hypoglycemic events was low in
both the groups, but was higher in the
vildagliptin-treated patients (6.4%, HbA1c
*7%) compared with placebo-treated patients
(1.3%, HbA1c *8%). None of the patients
reported any severe hypoglycemia that
required assistance of another person. Similar
findings about a very low proportion of patients
experiencing hypoglycemic events with
vildagliptin treatment were reported in
previous studies [13–15]. Efficacy and safety
Fig. 3 a Mean HbA1c (%) by treatment and visit.
Unadjusted means and standard errors (vertical bars) are
presented. Study endpoint is deﬁned as the ﬁnal available
post-randomization assessment obtained at any visit
(scheduled or unscheduled), prior to the start of major
changes in insulin background therapy, up to the ﬁnal
scheduled visit including week 12. bid twice daily, BL
baseline, EP endpoint, HbA1c glycated hemoglobin.
b Change in HbA1c (%) from baseline to study endpoint.
*p\0.001. Study endpoint is deﬁned as the ﬁnal available
post-randomization assessment obtained at any visit
(scheduled or unscheduled), prior to the start of major
changes in insulin background therapy, up to the ﬁnal
scheduled visit including week 12. bid twice daily, BL
baseline, HbA1c glycated hemoglobin, SE standard error
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Table 2 HbA1c (%) responder rates (FAS)
Responder criteria Vildagliptin
50 mg bid (n5 78)
Placebo
(n 5 78)
N0a 78 (100) 78 (100)
Responder criterion
At least one criterion met 67 (85.9)* 21 (26.9)*
HbA1c B6.5%b 23/77 (29.9)* 2/78 (2.6)*
HbA1c\7.0%b 38/76 (50.0)* 3/77 (3.9)*
HbA1c\7.0% in patients with baseline HbA1c B8.0%c 33/42 (78.6)* 3/37 (8.1)*
HbA1c reduction C1.0%a 38 (48.7)* 5 (6.4)*
HbA1c reduction C0.5%a 62 (79.5)* 20 (25.6)*
Chi-square test for vildagliptin 50 mg bid vs. placebo
bid twice daily, HbA1c glycated hemoglobin, FAS full analysis set
* p\0.001
a Number (percentage) of patients with both baseline and endpoint HbA1c measurements, which were used as the
denominator unless, speciﬁed otherwise
b Denominator includes only patients with baseline HbA1c C7% ([6.5%) and endpoint HbA1c measurement
c Denominator includes only patients with 7% Bbaseline HbA1c B8% and endpoint HbA1c measurement
Table 3 Mean changes in HbA1c (%) from baseline to endpoint by subgroups
Treatment n Baseline mean (SE) Mean change (SE) Range
With metformin
Vildagliptin 50 mg bid 34 8.2 (0.2) -1.1 (0.1) (-2.2 to -0.1)
Placebo 34 8.3 (0.2) -0.1 (0.1) (-1.1 to 1.2)
Without metformin
Vildagliptin 50 mg bid 44 8.0 (0.1) -0.9 (0.1) (-2.4 to 0.7)
Placebo 44 8.0 (0.1) -0.1 (0.1) (-1.2 to 2.0)
Insulin type: long-acting or intermediate-acting
Vildagliptin 50 mg bid 46 8.0 (0.1) -0.9 (0.1) (-2.2 to 0.7)
Placebo 45 8.3 (0.1) -0.0 (0.1) (-1.2 to 2.0)
Insulin type: pre-mixed
Vildagliptin 50 mg bid 32 8.2 (0.2) -1.2 (0.1) (-2.4 to -0.3)
Placebo 33 8.0 (0.2) -0.2 (0.1) (-1.1 to 1.0)
Baseline is the measurement obtained on day 1 or the sample obtained on an earlier visit (scheduled or unscheduled) which
was closest to day 1, if day 1 measurement is missing. Study endpoint is deﬁned as the ﬁnal available post-randomization
assessment obtained at any visit (scheduled or unscheduled), prior to the start of major changes in insulin background
therapy, up to the ﬁnal scheduled visit including week 12
bid twice daily, HbA1c glycated hemoglobin, SE standard error
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findings observed from this study are in line
with data obtained from other gliptins
including alogliptin, saxagliptin, and
linagliptin as add-on to insulin in terms of
effective HbA1c reduction and similar incidence
rates of AEs [16–18].
Insulin therapy is generally associated with
increased risk of hypoglycemia, which often is a
barrier in achieving good glycemic control.
Prolonged use of insulin is associated with IAH,
which could also increase the risk of
hypoglycemia and complications associated
with it [10, 11]. Furthermore, intensive glucose
control resulted in severe hypoglycemia requiring
assistance in 0.4–1.5% as reported in ADVANCE
(ClinicalTrials.gov Identifier, NCT00145925) and
ACCORD trials (ClinicalTrials.gov Identifier,
NCT00000620) [19, 20].
Fig. 4 a Mean FPG (mmol/L) by treatment and visit.
Unadjusted means and standard errors (vertical bars) are
presented. bid twice daily, BL baseline, EP endpoint, FPG
fasting plasma glucose. b Change in FPG (mmol/L) from
baseline to endpoint by treatment. *p\0.001. Baseline is
measurement obtained on day 1, or the sample obtained
on an earlier visit (scheduled or unscheduled) which was
closest to day 1, if day 1 measurement is missing. Study
endpoint is deﬁned as the ﬁnal available post-randomiza-
tion assessment obtained at any visit (scheduled or
unscheduled), prior to the start of major changes in
insulin background therapy, up to the ﬁnal scheduled visit
including week 12. bid twice daily, BL baseline, FPG
fasting plasma glucose, SE standard error
Table 4 Number (%) of patients who reported common
AEs by preferred term (safety set)
Preferred term, n (%) Vildagliptin
50 mg bid (n5 78)
Placebo
(n5 78)
Any preferred term 36 (46.2) 34 (43.6)
Nasopharyngitis 10 (12.8) 11 (14.1)
Hyperhidrosis 8 (10.3) 2 (2.6)
Hunger 7 (9.0) 3 (3.8)
Tremor 7 (9.0) 4 (5.1)
Asthenia 6 (7.7) 6 (7.7)
Hypoglycemia 5 (6.4) 1 (1.3)
Blood glucose decreased 2 (2.6) 2 (2.6)
Constipation 2 (2.6) 1 (1.3)
Dizziness 2 (2.6) 3 (3.8)
Gastroenteritis 2 (2.6) 0
Palpitations 2 (2.6) 1 (1.3)
Vision blurred 2 (2.6) 2 (2.6)
Abdominal distension 1 (1.3) 2 (2.6)
Cold sweat 0 2 (2.6)
Miliaria 0 2 (2.6)
Non-cardiac chest pain 0 2 (2.6)
Pharyngitis 0 2 (2.6)
A patient with multiple occurrences of an AE under one
treatment was counted only once in the AE category
AE adverse event, bid twice daily
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In the present study, addition of vildagliptin
significantly reduced HbA1c by 1.0% in patients
treated with a stable dose of insulin. In
addition, there were no occurrences of any
severe hypoglycemic events, suggesting that a
combination therapy of insulin and vildagliptin
might be effective in achieving glycemic control
without additional risk of hypoglycemia.
The use of combination therapy with insulin
and incretins, including DPP-4 inhibitors such
as vildagliptin could be beneficial in patients
with T2DM inadequately controlled on insulin
due to their complementary mechanisms of
action [21].
CONCLUSIONS
Treatment with vildagliptin 50 mg bid as
add-on to insulin, with or without metformin
therapy resulted in a statistically significant
reduction in HbA1c in Japanese patients with
T2DM. Despite significant improvement in
glycemic control, few patients experienced
hypoglycemic events with vildagliptin.
Importantly, no patient experienced severe
hypoglycemia requiring assistance of another
person. The addition of vildagliptin could be an
effective treatment option in Japanese patients
inadequately controlled on insulin regardless of
concomitant metformin therapy.
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Table 5 Number of patients who experienced







Number (%) of patients with
at least one hypoglycemic event
5 (6.4) 1 (1.3)
Number of patients with
One hypoglycemic event 3 (3.8) 1 (1.3)
Two hypoglycemic events 1 (1.3) 0
[2 hypoglycemic events 1 (1.3) 0




Grade 1a 9 (100) 1 (100)
Grade 2b 0 0
Suspected grade 2c 0 0
Data are expressed as n (%), unless speciﬁed otherwise
bid twice daily
Hypoglycemic events were deﬁned as: a Grade 1: symptoms
suggestive of hypoglycemia, where the patient was able to
initiate self-treatment and plasma glucose measurement
was\56 mg/dL
b Grade 2: symptoms suggestive of hypoglycemia, where
the patient was unable to initiate self-treatment and
plasma glucose measurement was\56 mg/dL
c Suspected grade 2: symptoms suggestive of hypoglycemia,
where the patient was unable to initiate self-treatment and
no plasma glucose measurement was available
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